Tildrakizumab for Prevention of Acute Graft-Versus-Host Disease

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 1, 2020

Primary Completion Date

June 1, 2024

Study Completion Date

June 17, 2024

Conditions

Hematologic Malignancies

Interventions

DRUG

Tildrakizumab

100 mg will be injected subcutaneously on Day -1, Day 28 ± 3, Day 112 ± 7, Day 196 ± 14, and Day 280 ± 14.

Trial Locations (1)

Froedtert Hospital and the Medical College of Wisconsin, Milwaukee

All Listed Sponsors

lead

Medical College of Wisconsin

OTHER

NCT04112810 - Tildrakizumab for Prevention of Acute Graft-Versus-Host Disease | Biotech Hunter | Biotech Hunter